First Manhattan’s PDS Biotechnology PDSB Stock Holding History

First Manhattan’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,000	Closed	-$11.5K	–	781
2025 Q4	$11.5K	Hold	15,000	–	–	﹤0.01%	729
2025 Q3	$15.2K	Hold	15,000	–	–	﹤0.01%	714
2025 Q2	$19.9K	Hold	15,000	–	–	﹤0.01%	696
2025 Q1	$17.9K	Buy	+15,000	New	+$21.3K	﹤0.01%	676
2023 Q2	–	Sell	-271,576	Closed	-$1.67M	–	1523
2023 Q1	$1.67M	Hold	271,576	–	–	0.01%	350
2022 Q4	$3.58M	Hold	271,576	–	–	0.01%	265
2022 Q3	$806K	Hold	271,576	–	–	﹤0.01%	439
2022 Q2	$991K	Hold	271,576	–	–	﹤0.01%	420
2022 Q1	$1.68M	Hold	271,576	–	–	0.01%	388
2021 Q4	$2.2M	Buy	271,576 +75,757	+39%	+$815K	0.01%	332
2021 Q3	$2.92M	Buy	195,819 +22,888	+13%	+$285K	0.01%	281
2021 Q2	$2.17M	Buy	172,931 +23,864	+16%	+$186K	0.01%	320
2021 Q1	$678K	Hold	149,067	–	–	﹤0.01%	475
2020 Q4	$319K	Hold	149,067	–	–	﹤0.01%	584
2020 Q3	$347K	Hold	149,067	–	–	﹤0.01%	563
2020 Q2	$299K	Hold	149,067	–	–	﹤0.01%	577
2020 Q1	$108K	Buy	+149,067	New	+$258K	﹤0.01%	725

Other funds holding PDSB

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

First Manhattan's PDSB Position: Q1 2026 in Review

First Manhattan sold out of PDS Biotechnology (PDSB) in Q1 2026, closing a stake of 15,000 shares — an estimated $11.5K sold.

First Manhattan first reported a position in PDSB in Q1 2020 and held it in 17 quarters. The position peaked at $3.58M in Q4 2022. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

First Manhattan reported no remaining PDS Biotechnology position as of Q1 2026 after selling out during the quarter.
First Manhattan sold 15,000 PDS Biotechnology shares in Q1 2026, an estimated $11.5K.
First Manhattan first reported a position in PDS Biotechnology in Q1 2020 and held it in 17 quarters.
First Manhattan's PDS Biotechnology position peaked at $3.58M in Q4 2022.
41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on First Manhattan's 13F filing for Q1 2026, filed 15 May 2026.